Key Highlights

  • BillionToOne shares closed at $124.90 today, up 9.16%.
  • The rally is fueled by favorable Medicare reimbursement developments, including preliminary 2027 CMS lab fee schedule data showing oncology test rates rising 29%.
  • UNITY Fetal Risk prenatal reimbursement is jumping 112%, which management characterized as neutral for prenatal and positive for oncology testing ahead of anticipated MolDX coverage decisions.
  • The move extends gains following strong second-quarter results, with 64% Revenue growth and raised full-year guidance.

Favorable Medicare Reimbursement Developments Drive the Rally

BillionToOne (NASDAQ:BLLN) shares closed sharply higher today, extending a multi-week rally driven by favorable Medicare reimbursement developments. Preliminary 2027 CMS lab fee schedule data showed oncology test rates rising 29% and UNITY Fetal Risk prenatal reimbursement jumping 112%, with management characterizing the net impact as neutral for prenatal testing and positive for oncology testing ahead of anticipated MolDX coverage decisions by year-end.

Strong Underlying Growth Reinforces the Momentum

The move extends gains following strong second-quarter results, with 64% revenue growth and raised full-year guidance of $450 million to $465 million, alongside $548.6 million in cash on hand supporting continued Investment in the company's testing platform. The rally continues even as insiders, including the CEO and general counsel, have sold shares under 10b5-1 plans, and the stock trades at a premium valuation with a consensus price target of $125.88.

A Precision Molecular Diagnostics Company

BillionToOne is a precision molecular diagnostics company headquartered in Menlo Park, California, founded in 2016, whose proprietary Quantitative Counting Templates platform enables highly accurate, single-molecule level detection and quantification of DNA, powering its core product lines across two key verticals: prenatal screening and oncology. Its flagship offerings include UNITY Complete, a non-invasive prenatal test assessing fetal risk for aneuploidies and recessive conditions, and the Northstar liquid biopsy portfolio, which identifies tumor mutations and monitors cancer treatment response with high sensitivity.